Pharmacokinetics/Pharmacodynamics of Antiarrhythmic Drugs
Julia H Indik1, Raymond L Woosley2
1Department of Medicine, Sarver Heart Center, University of Arizona College of Medicine, 1501 North Campbell Avenue, Tucson, AZ 85724-5037, USA.
Abstract:
This article describes the pharmacology of antiarrhythmic medications. Although these medications are broadly considered in terms of their blockade of either sodium or potassium channels, they act by a variety of pharmacodynamic mechanisms. Elimination may be via hepatic metabolism or renal mechanisms, or a combination. In particular, interactions between antiarrhythmic medications and other drugs that interfere with hepatic metabolism by P450 enzymes is a source for toxicity.
Related Concept Videos
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Pharmacokinetics: Drug–Drug Interactions
Pharmacodynamics: Overview and Principles
Most drugs' effects result from their interactions with drug receptors or targets within the body. These interactions trigger specific responses at the cellular or systemic level. Drug receptors can be found on the surfaces of cells or...


